New hope for tough blood cancers: venetoclax combo enters human trials

NCT ID NCT05292664

Recruiting now Disease control Sponsor: Andrew E. Place, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether adding the drug venetoclax to standard chemotherapy is safe and tolerable for children, adolescents, and young adults with high-risk blood cancers like MDS, AML, and ALL. About 30 participants will receive different combinations of chemotherapy drugs along with venetoclax. The main goal is to find the best dose and watch for side effects, not yet to prove the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Venetoclax (Venclexta) combined with chemotherapy drugs including azacitidine, cytarabine, methotrexate, and calaspargase pegol
What this could lead to: If it works, this could lead to a safer, more effective treatment option for children and young adults with hard-to-treat blood cancers.
What could go wrong: This is a very early (Phase 1) trial with only 30 participants, focused on safety and dosing. The combination may cause serious side effects, and it's too soon to know if it will improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute leukemia of ambiguous lineage acute lymphoblastic leukemia lymphoblastic lymphoma myelodysplastic syndrome Myelodysplastic Syndromes Neoplasm Metastasis Precursor Cell Lymphoblastic Leukemia-Lymphoma Recurrence refractory precursor T-lymphoblastic lymphoma/leukemia therapy related acute myeloid leukemia and myelodysplastic syndrome therapy-related myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE IN RELAPSE ACUTE LYMPHOBLASTIC LEUKEMIA WITH FAILED REMISSION ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE LYMPHOBLASTIC LYMPHOMA, IN RELAPSE LYMPHOBLASTIC LYMPHOMA, REFRACTORY MYELODYSPLASTIC SYNDROMES, DE NOVO MYELODYSPLASTIC SYNDROMES, PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROMES, SECONDARY THERAPY-RELATED MYELODYSPLASTIC SYNDROME TREATMENT-RELATED ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Ann & Robert H Lurie Children's Hospital of Chicago
RECRUITING

Chicago, Illinois, 60611, United States
Children's Healthcare of Atlanta at Arthur M. Blank Hospital
RECRUITING

Atlanta, Georgia, 30329, United States
Children's Hospital Colorado
RECRUITING

Aurora, Colorado, 80045, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
University of California San Francisco-Benioff Children's Hospital
RECRUITING

San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.